Characteristics of known drug space. Natural products, their derivatives and synthetic drugs.

Known drug space (KDS) was analysed for the occurrence of natural products and their derivatives. A database of 1000 marketed drugs was compiled. It was found that 10% of the drugs on the market are unaltered natural products, 29% are their derivatives (semi-synthetics) and the rest (61%) have a synthetic origin. Of the natural products, and their derivatives, polycyclic drugs were the most abundant at 21% followed by simple drugs (16%) and steroids (15%). In regard to the molecular descriptors the natural products had larger statistical means and standard deviations than their synthetic counterparts. It was found that KDS occupies a larger volume in chemical space with respect to drug-like chemicals, i.e., KDS fully encompasses drug-like chemical space with the parameters of molecular weight≤800 g mol(-1), log P≤6.5, hydrogen bond acceptors≤15, hydrogen bond donors≤7, polar surface area≤180 Å2, and rotatable bonds≤17. Only 13% of the drugs analysed are outside one or more of these parameters. The definition of KDS gives drug designers a larger volume to work in compared to drug-like chemical space. However, the bulk of known drugs are found within the volume of drug-like chemical space.

[1]  G. Rishton Reactive compounds and in vitro false positives in HTS , 1997 .

[2]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[3]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[4]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[5]  Kristina Luthman,et al.  Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.

[6]  Jóhannes Reynisson,et al.  Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds. , 2009, European journal of medicinal chemistry.

[7]  A. Nassar,et al.  Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. , 2004, Drug discovery today.

[8]  Jóhannes Reynisson,et al.  Benchmarking the reliability of QikProp. Correlation between experimental and predicted values , 2008 .

[9]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[10]  Thomas Henkel,et al.  Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds. , 1999, Angewandte Chemie.

[11]  D. Newman,et al.  Impact of natural products on developing new anti-cancer agents. , 2009, Chemical reviews.

[12]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[13]  Maurice Dickins,et al.  Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.

[14]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[15]  J. Li Laughing Gas, Viagra, and Lipitor: The Human Stories behind the Drugs We Use , 2006 .

[16]  D J Newman,et al.  Natural products in drug discovery and development. , 1997, Journal of natural products.

[17]  M. A. Meyers Happy Accidents: Serendipity in Modern Medical Breakthroughs , 2007 .

[18]  Walter Sneader,et al.  Drug Discovery (The History) , 2005 .

[19]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[20]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[21]  Jóhannes Reynisson,et al.  Known drug space as a metric in exploring the boundaries of drug-like chemical space. , 2009, European journal of medicinal chemistry.

[22]  G. Schwartsmann,et al.  Natural products in anticancer therapy. , 2001, Current opinion in pharmacology.

[23]  John L. LaMattina,et al.  Book Review: Drug Truths: Dispelling the Myths About Pharma R&D , 2008 .

[24]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[25]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[26]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[27]  P. Hajduk,et al.  Cheminformatic tools for medicinal chemists. , 2010, Journal of medicinal chemistry.

[28]  M. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[29]  D. E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[30]  M. Waring,et al.  A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.

[31]  P. Clemons,et al.  Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes , 2010, Journal of the American Chemical Society.

[32]  J. Vederas,et al.  Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.

[33]  G. Rishton Nonleadlikeness and leadlikeness in biochemical screening. , 2003, Drug discovery today.

[34]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[35]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[36]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.